Literature DB >> 25077621

A simple and robust LC-MS/MS method for measuring sirolimus and everolimus in whole blood.

Chao Yuan1, Drew Payto, Jessica Gabler, Sihe Wang.   

Abstract

Therapeutic drug monitoring of immunosuppressants sirolimus and everolimus is mandatory and liquid chromatography tandem mass spectrometry (LC-MS/MS) is the preferred technology for the measurement. Due to the high hydrophobicity these analytes bind to reverse-phase columns tightly and need column heating to elute. Column heating not only requires extra instrument preparation but also causes permanent column damage if the heater is left on while elution pumps stop by the end of the run. The primary improvement in the current method was to elute the analytes at room temperature using special buffers. This new LC-MS/MS method has been validated for clinical use and offers improved simplicity and robustness by eliminating column heating yet with high sensitivity, precision and accuracy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25077621     DOI: 10.4155/bio.14.43

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  3 in total

1.  Accuracy evaluation of automated electrochemiluminescence immunoassay for everolimus and sirolimus compared to liquid chromatography-tandem mass spectrometry.

Authors:  Eun Jin Lee; Hyun-Ki Kim; Sunyoung Ahn; Woochang Lee; Hyun Soo Kim; Sail Chun; Won-Ki Min
Journal:  J Clin Lab Anal       Date:  2019-06-14       Impact factor: 2.352

2.  Development and Validation of a Bioanalytical LC-MS/MS Method for Simultaneous Determination of Sirolimus in Porcine Whole Blood and Lung Tissue and Pharmacokinetic Application with Coronary Stents.

Authors:  Thi-Thao-Linh Nguyen; Van-An Duong; Dang-Khoa Vo; Jeongae Jo; Han-Joo Maeng
Journal:  Molecules       Date:  2021-01-15       Impact factor: 4.411

3.  Comparison of LC-MS/MS and EMIT methods for the precise determination of blood sirolimus in children with vascular anomalies.

Authors:  Yue-Tao Zhao; Hao-Ran Dai; Yue Li; Yuan-Yuan Zhang; Hong-Li Guo; Xuan-Sheng Ding; Ya-Hui Hu; Feng Chen
Journal:  Front Pharmacol       Date:  2022-09-06       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.